Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2025 value amounting to -$6.6 million.

  • Zevra Therapeutics' Other Non Operating Income rose 258.28% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.9 million, marking a year-over-year increase of 165027.41%. This contributed to the annual value of $6.2 million for FY2024, which is 34028.37% up from last year.
  • Zevra Therapeutics' Other Non Operating Income amounted to -$6.6 million in Q3 2025, which was up 258.28% from $135.4 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Other Non Operating Income high stood at $135.4 million for Q2 2025, and its period low was -$16.9 million during Q1 2021.
  • For the 3-year period, Zevra Therapeutics' Other Non Operating Income averaged around $12.0 million, with its median value being -$3.4 million (2025).
  • The largest annual percentage gain for Zevra Therapeutics' Other Non Operating Income in the last 5 years was 747007.83% (2025), contrasted with its biggest fall of 258.28% (2025).
  • Zevra Therapeutics' Other Non Operating Income (Quarter) stood at $789000.0 in 2021, then soared by 854.5% to $7.5 million in 2024, then tumbled by 187.15% to -$6.6 million in 2025.
  • Its Other Non Operating Income was -$6.6 million in Q3 2025, compared to $135.4 million in Q2 2025 and -$3.4 million in Q1 2025.